India, May 5 -- Biocon Biologics Ltd. (BBL), a global biosimilars company and a subsidiary of Biocon Ltd (BSE: 532523, NSE: BIOCON), has announced that it has secured extensive market access in the United States for its biosimilar Yesintek™ (ustekinumab-kfce), a counterpart to Stelara® (ustekinumab). The agreements span a wide range of health plans and collectively cover over 100 million lives.
Major pharmacy benefit managers and insurers have added Yesintek™ to their formularies. Express Scripts included it in its National Preferred Formulary starting March 21, 2025. Cigna followed suit, listing it on its commercial formulary from the same date. UnitedHealthcare has added Yesintek™ to its commercial formulary beginni...